Physician

Padmaja V Mallidi, M.D.

According to 2025 Medicare claims, Padmaja Mallidi, M.D. (NPI: 1629044821) practices hematology/oncology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (NPI: 1487621496; TIN: 541922084) and primary practice location at 24014-2419. Mallidi is affiliated with the Doctors Connected (ACO ID: A4949), participating under the MSSP model.

Mallidi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 761 traditional Medicare patients, billed 142,167 HCPCS/CPT codes, and received $2,876,524 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,362 prescription claims across 249 beneficiaries totaling $4,425,374 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 87 claims. Open Payments data shows 1 records totaling $131. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,726,993 to $2,876,524. Similarly, Part D prescription costs have risen steadily, from $948,811 to $4,425,374. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	799	142,018	$1,726,993
2016	809	130,879	$1,655,994
2017	872	149,948	$2,522,895
2018	862	162,744	$3,159,088
2019	842	173,936	$2,770,205
2020	891	198,995	$3,402,159
2021	881	193,928	$3,651,375
2022	938	194,443	$3,949,849
2023	899	181,601	$3,277,279
2024	761	142,167	$2,876,524

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	169	876	$948,811
2016	185	1,062	$1,137,085
2017	180	1,121	$2,300,552
2018	212	1,196	$2,581,481
2019	232	1,334	$3,045,361
2020	247	1,456	$3,816,980
2021	275	1,417	$4,346,768
2022	277	1,424	$5,141,887
2023	286	1,487	$3,609,461
2024	249	1,362	$4,425,374

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	27	120	$10,974
2016	N/R	111	$15,352
2017	N/R	60	$12,423
2018	38	162	$23,534
2019	71	193	$20,481
2020	79	303	$23,007
2021	70	211	$14,451
2022	54	166	$6,148
2023	73	233	$32,396
2024	N/R	87	$2,402

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	304	585	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	297	393	$60
80053	Blood test, comprehensive group of blood chemicals	443	1,302	$10
36415	Insertion of needle into vein for collection of blood sample	429	974	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	473	1,756	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	44	1,320	$591,278
Lenalidomide	Lenalidomide	38	1,064	$532,085
Revlimid	Lenalidomide	20	560	$384,791
Mekinist	Trametinib Dimethyl Sulfoxide	24	720	$371,865
Tafinlar	Dabrafenib Mesylate	25	750	$357,048

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	38	$1,661
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	31	$401
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	18	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$131	Tactile Systems Technology Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Padmaja V. Mallidi, M.D.?

Tedicare shows public-source Medicare data for Padmaja V. Mallidi, M.D. (NPI 1629044821), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Padmaja V. Mallidi, M.D. have ACO affiliation data?

Padmaja V. Mallidi, M.D. is shown with ACO affiliation data for Doctors Connected (MSSP, ACO ID A4949).

What billing organization is linked to Padmaja V. Mallidi, M.D.?

Padmaja V. Mallidi, M.D. is linked to ONCOLOGY AND HEMATOLOGY ASSOCIATES OF SOUTHWEST VIRGINIA, INC. (billing NPI 1487621496) in the available physician profile data.

Does Padmaja V. Mallidi, M.D. have Open Payments data?

Padmaja V. Mallidi, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.